Moving Green Early, (Nasdaq: IMNN) Just Dropped Breaking News On Their Phase 3 Trial

Imunon, Inc. (Nasdaq: IMNN) controls Thursday's top watchlist spot and is all over our AM radar.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Moving Green Early, (Nasdaq: IMNN) Just Dropped Breaking News On Their Phase 3 Trial July 30th Dear Reader, Imunon, Inc. (Nasdaq: IMNN) controls Thursday's top watchlist spot and is all over our AM radar. With a green move out of the bell under its belt, IMNN could start drawing some serious buzz from their breaking news today. Take a look: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2 Strong enrollment demonstrates the confidence of principal investigators from prestigious cancer institutions in the trial design and its potential for a successful outcome Enrollment ahead of plan across all study sites. Additional sites opening on pace with projections LAWRENCEVILLE, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) ("IMUNON" or "the Company"), a clinical-stage biotechnology company developing its novel DNA-mediated immunotherapies, today is providing a progress update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer. Since initiating the trial, the Company has observed rapid site activation and an enrollment rate that is exceeding its forecast. The trial advanced from protocol submission to site activation in approximately 6 months and from protocol approval to first patient randomized in approximately 2 months, a third of the time of the external industry benchmark. ... "The early momentum we are seeing in OVATION 3 reflects the strength of our clinical data, the quality of our sites and the commitment of the investigators and patients participating in the trial," said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. "We've seen enrollment build quarter after quarter, including through the early summer months when trials typically slow down, a trend we view as a strong signal of investigator and patient engagement. The consistent safety profile we've now observed across multiple studies further re-enforces our confidence in IMNN-001, uniquely designed to safely exploit the pluripotent capability of IL-12 to recruit the entirety of the patient's own immune system to fight cancer, as we continue to advance our pivotal Phase 3 OVATION 3 trial." ... Read the full article here. This is also critical to note. IMNN is a low float idea. Containing fewer than 4Mn shares in its float, there could be a strong potential for heightened volatility on a day to day basis. Review our initial report on (Nasdaq: IMNN) below and consider this idea for your radar. ----- Our latest profile was on fire right out of the gate. After it closed at $5.80 on Tuesday, it climbed to a Wednesday high of $7.55. That rapid move translated into a surge of approximately 30%. Now consider the following… For three decades, the standard treatment approach for newly diagnosed advanced ovarian cancer has gone virtually unchanged. That's not just a gap in innovation. That's a wall. And Imunon, Inc. (Nasdaq: IMNN) looks like it may be punching through. IMNN is a clinical-stage biopharmaceutical company with one driving mission: bringing a first-in-class DNA-based immunotherapy to bear on one of oncology's most stubborn cancers. The company's approach doesn't follow the conventional playbook of adding another layer of chemotherapy to an already burdened treatment regimen. Instead, it takes a fundamentally different biological route — one designed to mobilize the patient's own immune defenses against the tumor. The foundation of that route is the TheraPlas® nanoparticle platform, a proprietary gene delivery system that carries therapeutic DNA straight to the tumor site without relying on a viral vector. The lead asset, IMNN-001, uses this platform to express interleukin-12 (IL-12), a powerful immune-activating cytokine, directly within the abdominal cavity where ovarian tumors typically take hold. Earlier IL-12 therapies hit a wall because systemic delivery triggered severe toxicities. IMNN-001 solves that through localized delivery and a safety record that Phase 2 data backs up. In a randomized 112-patient OVATION 2 study, IMNN-001 extended median overall survival by 14.7 months over standard-of-care chemotherapy alone, 45.1 months versus 30.4 months in the control group. For the subgroup that also received PARP inhibitor maintenance therapy, that advantage grew to 24.2 months. The OVATION 2 findings were subsequently published in the peer-reviewed journal Gynecologic Oncology and earned an oral presentation slot at the 2025 ASCO Annual Meeting — one of oncology's most coveted scientific stages. The company has since advanced to Phase 3. The OVATION-3 trial is a 500-patient, randomized registrational study with overall survival as the primary endpoint. In June 2026, the independent Data Monitoring Committee completed a planned interim safety and efficacy review and recommended the trial continue without modification. That is a critical clinical milestone, confirming the program is progressing as designed and that no safety concerns have surfaced. Most recently, on July 23rd, 2026, Imunon presented new IMNN-001 data at the inaugural AACR Conference on Drug Discovery and Development in Boston. Imunon CEO, Stacy Lindborg, called the selection "an important recognition of Imunon's platform," and Chief Medical Officer Sebastien Hazard said the program "establishes a new paradigm for immunotherapy" in this indication. Taking a Closer Look: Imunon, Inc. (Nasdaq: IMNN) Imunon emerged from the former clinical-stage company Celsion Corporation, which rebranded in 2022 to signal its sharpened focus on DNA-based immunotherapy. Central to that focus is the proprietary TheraPlas® platform, a non-viral, nanoparticle delivery system engineered to transport therapeutic DNA into the tumor microenvironment, sidestepping both the manufacturing complexity and immunogenic risks that come with viral vector approaches. IMNN-001 is a DNA plasmid encoding interleukin-12 (IL-12), a powerful immune-activating cytokine, delivered directly into the abdominal cavity (intraperitoneally). Prior attempts to leverage IL-12 systemically fell short because the doses required for therapeutic benefit produced severe toxicity. Imunon's method circumvents that entirely. By delivering IL-12 locally via TheraPlas®, the treatment activates immune response at the tumor site — flipping an immunologically "cold" tumor into an active, immune-engaged environment, while minimizing exposure throughout the rest of the body. In OVATION 2, no serious immune-related adverse events were recorded. The pipeline reaches well beyond ovarian cancer. The same TheraPlas® platform is being explored in colorectal cancer, pancreatic cancer, and glioblastoma. IMNN-001 holds FDA Fast Track designation and Orphan Drug designation in both the United States and the European Union, a regulatory package that may help support an accelerated path toward a potential BLA submission. The Company's Must-See Product Pipeline 6 Potential Catalysts That Could Make (Nasdaq: IMNN) Worth Watching #1. Phase 3 OVATION-3 Enrollment Is Running Ahead Of Projections: IMNN's clinical momentum has beaten initial expectations, with enrollment tracking ahead of schedule and 50% enrollment now targeted for Q1 2028, per the company's Q1 2026 update. #2. Data Safety Committee Greenlit The Trial In June: The independent Data Monitoring Committee reviewed OVATION-3 in June 2026 and recommended the study continue without changes, a major regulatory checkpoint confirming the integrity of the trial's safety profile and design. #3. FDA Protocol Alignment Strips Away Key Regulatory Risk: The FDA has confirmed alignment with IMNN on the OVATION-3 protocol and the pathway to BLA filing, a pivotal regulatory achievement that substantially reduces uncertainty around the approval process. #4. Analyst's $25 Price Target Implies Potential Quadruple-Digit Upside: A research analyst at Zacks Small Cap Research has set a $25 price target on IMNN. Measured from Wednesday's close, that target implies a potential 1,400%+ upside. #5. A Tight Float Could Create A Potential Environment For Heightened Volatility: With an estimated float of roughly 3.81Mn shares, the conditions for heightened volatility may be firmly in place. #6. AACR Conference Presentation Adds Scientific Credibility: Imunon was invited to present IMNN data at the inaugural AACR Conference on Drug Discovery and Development in Boston on July 23rd, 2026, providing additional peer-level scientific validation for the TheraPlas® platform and its clinical outcomes. Final Take Imunon, Inc. (Nasdaq: IMNN) is a clinical-stage company carrying a development story that's hard to ignore. Three decades without a meaningful step forward in frontline ovarian cancer treatment is the type of stagnation that marks entire careers in medicine, and one that could define a company's legacy if they're the one to change it. We're launching coverage on Imunon, Inc. (Nasdaq: IMNN). Watch for updates coming soon. More to follow shortly. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice